(NUVB) – Press Releases
-
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
-
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
-
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
-
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
-
Nuvation Bio Announces Departure of Chief Financial Officer
-
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
-
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
-
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
-
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
-
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
-
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
-
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
-
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
-
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
-
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors
-
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones
-
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
-
Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
-
Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer
-
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference
-
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update
-
Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update
-
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas
Back to NUVB Stock Lookup
